Semax – Comprehensive Research Overview (2026)

Semax is a synthetic heptapeptide analog of ACTH fragment 4–10 (Met-Glu-His-Phe-Pro-Gly-Pro) developed in Russia. It is approved in Russia for stroke recovery, cognitive disorders, and optic nerve disease. Semax is primarily researched for its neuroprotective, nootropic, and neurorestorative properties. It strongly upregulates BDNF and NGF, making it one of the most potent neurotrophic peptides available for research.

→ View Semax (for laboratory research use only)

Chemical Structure and Properties

  • Sequence: Met-Glu-His-Phe-Pro-Gly-Pro (ACTH 4–10 analog with Pro-Gly-Pro stabilizing extension)
  • Molecular Weight: ≈813 Da
  • Form: Lyophilized powder or nasal spray solution
  • Key Feature: Potent BDNF and NGF upregulator; approved in Russia for neurological indications

Mechanism of Action

  • Strongly upregulates BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) in the hippocampus and cortex.
  • Modulates dopaminergic and serotonergic neurotransmission.
  • Reduces neuroinflammation and oxidative stress in CNS tissue.
  • Promotes neuronal survival, synaptic plasticity, and neurogenesis.
  • Activates melanocortin receptors (MC4R) contributing to cognitive and mood effects.

Clinical Evidence and Research Findings

Multiple Russian clinical trials demonstrate efficacy for ischemic stroke recovery, cognitive impairment, and optic nerve atrophy. Semax is approved and widely used in Russia as a nasal spray. Western research is growing, with interest in its nootropic, neuroprotective, and antidepressant properties. No large Western Phase 3 trials exist.

→ Interested in researching Semax? View Product Options

Benefits (Research & Clinical Observations)

  • Enhanced cognitive function, memory, and focus
  • Neuroprotection and neuroregeneration after injury
  • Antidepressant and anxiolytic effects
  • Stroke recovery support
  • Potential for neurodegenerative disease research

Typical Dosing Protocols (Off-Label / Research)

  • Nasal spray: 200–900 μg per nostril, 1–3 times daily (approved Russian protocol)
  • Subcutaneous: 200–600 μg once or twice daily
  • Cycles: 2–4 weeks on, with breaks

Safety Profile and Side Effects

Semax has an excellent safety profile with decades of use in Russia. Common side effects: mild nasal irritation (spray), transient headache. No significant dependence or withdrawal reported.

Summary

Semax is a potent neurotrophic and neuroprotective peptide with regulatory approval in Russia and a strong safety record. Its BDNF/NGF-upregulating mechanism makes it uniquely valuable for cognitive, neurological, and mood research. As with all compounds in this library, Semax is not FDA-approved and should only be considered under qualified medical supervision.

For Laboratory Research Use View Semax →

Disclaimer This overview is strictly educational and based on publicly available scientific literature as of April 2026. It does not constitute medical advice. Always consult a qualified healthcare professional and comply with all applicable laws and regulations.